-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
The GlaxoSmithKline (GSK) shingles vaccine Shingrix was approved for marketing in October 2017, and it almost broke through the blockbuster sales (sales of US$999 million) in its first full year on the market
On Monday, the US FDA approved Shingrix to expand the applicable population for the vaccination of immune-compromised adults aged 18 and over to prevent shingles
This FDA approval has opened up a new group of people for Shingrix
This latest approval is based on research findings investigating the safety and effectiveness of Shingrix in adult patients undergoing stem cell transplantation and adult patients undergoing treatment for hematological malignancies
According to a press release issued by GSK, Shingrix is the first shingles vaccine approved for use in people with weakened immune functions
The FDA approval comes at a time when GSK is trying to get Shingrix back on track
In the early days of the COVID-19 pandemic, the Centers for Disease Control and Prevention (CDC) recommended that another vaccine should not be vaccinated within 2 weeks after the COVID-19 vaccine
Reference source: As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach
